Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)

• Company Description    Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States. Number of Employees: 167

• Price / Volume Information    Yesterday's Closing Price: $29.40 Daily Weekly Monthly 20 Day Moving Average: 430,063 shares Shares Outstanding: 55.31 (millions) Market Capitalization: $1,626.05 (millions) Beta: 1.72 52 Week High: $39.85 52 Week Low: $13.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.04% 7.80% 12 Week -7.23% -13.88% Year To Date 17.79% 7.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 Arsenal Yards Blvd. Suite 230 - Watertown,MA 02472 USA ph: 857-285-5300 fax: - investors@kymeratx.com http://www.kymeratx.com

• General Corporate Information    Officers Nello Mainolfi - Chief Executive Officer and President Bruce Booth - Chairman Bruce Jacobs - Chief Financial Officer Jeff Albers - Director Pamela Esposito - Director Peer Information Kymera Therapeutics, Inc. (CORR.) Kymera Therapeutics, Inc. (RSPI) Kymera Therapeutics, Inc. (CGXP) Kymera Therapeutics, Inc. (BGEN) Kymera Therapeutics, Inc. (GTBP) Kymera Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501575104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/08/23 Share - Related Items Shares Outstanding: 55.31 Most Recent Split Date: (:1) Beta: 1.72 Market Capitalization: $1,626.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 1.89% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.52 Price/Cash Flow: - Price / Sales: 34.84 EPS Growth vs. Year Ago Period: 1.41% vs. Previous Quarter: -16.67% Sales Growth vs. Year Ago Period: -1.62% vs. Previous Quarter: -41.35% ROE 03/31/23 - -34.15 12/31/22 - -33.84 09/30/22 - -34.20 ROA 03/31/23 - -26.74 12/31/22 - -26.60 09/30/22 - -26.40 Current Ratio 03/31/23 - 6.65 12/31/22 - 5.88 09/30/22 - 5.42 Quick Ratio 03/31/23 - 6.65 12/31/22 - 5.88 09/30/22 - 5.42 Operating Margin 03/31/23 - -340.80 12/31/22 - -330.60 09/30/22 - -334.72 Net Margin 03/31/23 - -340.80 12/31/22 - -330.60 09/30/22 - -334.72 Pre-Tax Margin 03/31/23 - -340.80 12/31/22 - -330.60 09/30/22 - -334.72 Book Value 03/31/23 - 8.35 12/31/22 - 8.93 09/30/22 - 9.35 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.21 12/31/22 - 0.25 09/30/22 - 0.13

Powered by Zacks Investment Research ©